What it is
Retatrutide is an investigational once-weekly injectable that agonises three receptors: GIP, GLP-1 and glucagon. Semaglutide hits one of those. Tirzepatide hits two. The third is the reason for the attention.
Glucagon receptor agonism is expected to increase energy expenditure rather than only suppress intake. If that holds, it is a mechanistically different lever from the one the approved drugs pull, which is the argument for why the early numbers came in where they did.
What the phase 2 trial showed
The phase 2 obesity trial, published in the New England Journal of Medicine in 2023, randomised 338 adults with obesity across several dose levels over 48 weeks. Mean body weight fell by roughly 24% on the 12 mg dose, against about 2% on placebo.
That is the largest average reduction reported for any agent in this class, approved or not. It is also a single mid-stage trial in 338 people.
Three reasons that number needs holding loosely
- Phase 2 trials are small and enrol selected populations. Effect sizes routinely come down in phase 3 when the population widens.
- Safety findings that change a drug's future usually emerge at phase 3 scale, not before. 338 people cannot rule out an uncommon serious event.
- There is no long-term data, no cardiovascular outcomes trial, and no withdrawal data. Nobody knows what happens after year two, or what happens when you stop.
What specifically is not known
- The dose-dependent increase in heart rate seen in phase 2 is unresolved.
- The hepatic effects of sustained glucagon receptor agonism have not been characterised over long periods in humans.
- There is no approved dosing schedule, because there is no approval.
- The rodent thyroid C-cell signal that carries a boxed warning across this class has not been excluded for retatrutide.
Where the trials are
The phase 3 TRIUMPH programme is underway. Until it reports, everything anybody knows about retatrutide in humans rests on one mid-stage trial and whatever has been presented at conferences since.
The part that matters most
Retatrutide cannot legally be prescribed. The only lawful route to it is enrolment in a clinical trial.
Everything sold online under that name is research-use material. It is not manufactured, tested or labelled for human use. Its identity and purity rest on the seller's own paperwork. There is no clinician, no pharmacy and no recourse.
Of everything we cover, this is where the distance between the published science and what people are actually injecting is widest. The trial results are genuinely impressive. They are results about a specific manufactured compound administered under supervision, and they do not transfer to a vial bought from a website.
Sources
- Jastreboff et al., Triple-hormone-receptor agonist retatrutide for obesity, New England Journal of Medicine, 2023
- ClinicalTrials.gov, TRIUMPH programme records